Literature DB >> 34273739

Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy.

Leslie Grayson1, Steve Ampah2, Kathleen Hernando3, Pongkiat Kankirawatana4, Tyler Gaston3, Gary Cutter2, Jerzy P Szaflarski5, Elizabeth Martina Bebin3.   

Abstract

OBJECTIVE: To assess the longitudinal impact of highly purified cannabidiol (CBD) on the electroencephalogram (EEG) of children and adults.
METHODS: Participants received an EEG prior to starting CBD, after approximately 12 weeks of CBD (FU1) and after approximately one year of CBD therapy (FU2). Longitudinal changes in five EEG measures (background frequency, focal slowing, reactivity, frequency of interictal, and ictal discharges) were examined following CBD exposure. Data were compared between pediatric and adult groups at two follow-up time points and within groups over time. Population-averaged models with generalized estimation equations or linear mixed effects models were used to analyze data where appropriate. Correlation analysis was used to assess any association between changes in seizure frequency and changes in EEG interictal discharge (IED) frequency. An alpha level of 5% was used to assess statistical significance.
RESULTS: At FU1, the adult group showed significant decrease in IED/minute (IDR 0.07, 95% CI [0.04, 0.14], P < 0.001); a nonsignificant decrease was observed among children (IDR 0.87, 95% CI [0.47, 0.64], P = 0.67). The difference in changes over time between participant groups was significant after adjusting for last CBD dose (IDR 11.8, 95% CI [4.86, 28.65], P < 0.0001). At FU2 both groups showed significant reduction from baseline after controlling for last CBD dose. This decrease was more pronounced in children (IDR 15.38, 95% CI [4.93, 47.99], P < 0.001). There was no significant correlation between changes in seizure frequency and EEG IED frequency at each timepoint (P = 0.542, 0.917 and 0.989 from baseline to FU1, FU1 to FU2 and baseline to FU2, respectively). SIGNIFICANCE: This longitudinal EEG study shows that highly-purified plant-derived CBD has positive effects on interictal epileptiform discharge frequency but no effects on other EEG measures. The effect of CBD does not appear to be dose or treatment-duration dependent.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabidiol (CBD); Electroencephalogram (EEG); Epidiolex®; Epilepsy; Interictal discharges (IED)

Year:  2021        PMID: 34273739     DOI: 10.1016/j.yebeh.2021.108190

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  2 in total

1.  Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study.

Authors:  Cristian Eduardo Navarro
Journal:  Neurol Sci       Date:  2022-09-21       Impact factor: 3.830

2.  Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.

Authors:  Ellen N Hurley; Carolyn J Ellaway; Alexandra M Johnson; Linda Truong; Rebecca Gordon; Peter Galettis; Jennifer H Martin; John A Lawson
Journal:  Epilepsia       Date:  2022-04-20       Impact factor: 6.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.